Current evidence and future perspectives for curcumin and its analogues as promising adjuncts to oxaliplatin: state-of-the-art

Mahtab Zangui, Stephen Atkin, Muhammed Majeed, Amirhossein Sahebkar

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Curcumin is a multifunctional phytochemical that has documented anti-oxidant, anti-inflammatory and anti-tumor properties. The anti-tumor effect of curcumin has been widely investigated, both as a single ingredient and in combination with chemotherapeutic agents. Oxaliplatin is a third-generation platinum agent with established effectiveness in multiple malignancies including gastroesophageal, colorectal, pancreas, ovarian, breast and head and neck cancers. The effects of curcumin and its synthetic analogues in combination with oxaliplatin have been studied in a variety of malignant cell lines in vitro and in vivo, providing evidence supporting the beneficial effects of curcumin as an adjunct to oxaliplatin, though dose, combination ratio and the timing of exposure to the agents are covariates that may affect the therapeutic efficacy and need to be determined. This review provides a summary of the studies investigating the effects of curcumin and its analogues, as adjuvants to oxaliplatin treatment in malignant cell lines and experimental tumor models. Addition of curcumin as an adjunct to oxaliplatin enhances oxaliplatin's toxicity in malignant cells, which potentially allows an oxaliplatin dose reduction and decreasing the adverse effects of chemotherapy. Curcumin has also been studied in several nonmalignant cell types and has been shown to exert cytoprotective properties against oxaliplatin's off-target toxicities. Despite all of the promising evidence to date, there is a scarcity of supportive evidence from clinical trials on the adjuvant use of curcumin, which needs future translational and clinical studies.

Original languageEnglish
Pages (from-to)343-356
Number of pages14
JournalPharmacological Research
Volume141
DOIs
Publication statusPublished - 1 Mar 2019

Fingerprint

oxaliplatin
Curcumin
Neoplasms
Phytochemicals
Head and Neck Neoplasms
Platinum
Tumor Cell Line
Oxidants

Keywords

  • Adjuvant
  • Chemotherapy
  • Curcumin
  • Oxaliplatin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Current evidence and future perspectives for curcumin and its analogues as promising adjuncts to oxaliplatin : state-of-the-art. / Zangui, Mahtab; Atkin, Stephen; Majeed, Muhammed; Sahebkar, Amirhossein.

In: Pharmacological Research, Vol. 141, 01.03.2019, p. 343-356.

Research output: Contribution to journalReview article

@article{c6a943075ac84648abd2e79ddcf80642,
title = "Current evidence and future perspectives for curcumin and its analogues as promising adjuncts to oxaliplatin: state-of-the-art",
abstract = "Curcumin is a multifunctional phytochemical that has documented anti-oxidant, anti-inflammatory and anti-tumor properties. The anti-tumor effect of curcumin has been widely investigated, both as a single ingredient and in combination with chemotherapeutic agents. Oxaliplatin is a third-generation platinum agent with established effectiveness in multiple malignancies including gastroesophageal, colorectal, pancreas, ovarian, breast and head and neck cancers. The effects of curcumin and its synthetic analogues in combination with oxaliplatin have been studied in a variety of malignant cell lines in vitro and in vivo, providing evidence supporting the beneficial effects of curcumin as an adjunct to oxaliplatin, though dose, combination ratio and the timing of exposure to the agents are covariates that may affect the therapeutic efficacy and need to be determined. This review provides a summary of the studies investigating the effects of curcumin and its analogues, as adjuvants to oxaliplatin treatment in malignant cell lines and experimental tumor models. Addition of curcumin as an adjunct to oxaliplatin enhances oxaliplatin's toxicity in malignant cells, which potentially allows an oxaliplatin dose reduction and decreasing the adverse effects of chemotherapy. Curcumin has also been studied in several nonmalignant cell types and has been shown to exert cytoprotective properties against oxaliplatin's off-target toxicities. Despite all of the promising evidence to date, there is a scarcity of supportive evidence from clinical trials on the adjuvant use of curcumin, which needs future translational and clinical studies.",
keywords = "Adjuvant, Chemotherapy, Curcumin, Oxaliplatin",
author = "Mahtab Zangui and Stephen Atkin and Muhammed Majeed and Amirhossein Sahebkar",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.phrs.2019.01.020",
language = "English",
volume = "141",
pages = "343--356",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Current evidence and future perspectives for curcumin and its analogues as promising adjuncts to oxaliplatin

T2 - state-of-the-art

AU - Zangui, Mahtab

AU - Atkin, Stephen

AU - Majeed, Muhammed

AU - Sahebkar, Amirhossein

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Curcumin is a multifunctional phytochemical that has documented anti-oxidant, anti-inflammatory and anti-tumor properties. The anti-tumor effect of curcumin has been widely investigated, both as a single ingredient and in combination with chemotherapeutic agents. Oxaliplatin is a third-generation platinum agent with established effectiveness in multiple malignancies including gastroesophageal, colorectal, pancreas, ovarian, breast and head and neck cancers. The effects of curcumin and its synthetic analogues in combination with oxaliplatin have been studied in a variety of malignant cell lines in vitro and in vivo, providing evidence supporting the beneficial effects of curcumin as an adjunct to oxaliplatin, though dose, combination ratio and the timing of exposure to the agents are covariates that may affect the therapeutic efficacy and need to be determined. This review provides a summary of the studies investigating the effects of curcumin and its analogues, as adjuvants to oxaliplatin treatment in malignant cell lines and experimental tumor models. Addition of curcumin as an adjunct to oxaliplatin enhances oxaliplatin's toxicity in malignant cells, which potentially allows an oxaliplatin dose reduction and decreasing the adverse effects of chemotherapy. Curcumin has also been studied in several nonmalignant cell types and has been shown to exert cytoprotective properties against oxaliplatin's off-target toxicities. Despite all of the promising evidence to date, there is a scarcity of supportive evidence from clinical trials on the adjuvant use of curcumin, which needs future translational and clinical studies.

AB - Curcumin is a multifunctional phytochemical that has documented anti-oxidant, anti-inflammatory and anti-tumor properties. The anti-tumor effect of curcumin has been widely investigated, both as a single ingredient and in combination with chemotherapeutic agents. Oxaliplatin is a third-generation platinum agent with established effectiveness in multiple malignancies including gastroesophageal, colorectal, pancreas, ovarian, breast and head and neck cancers. The effects of curcumin and its synthetic analogues in combination with oxaliplatin have been studied in a variety of malignant cell lines in vitro and in vivo, providing evidence supporting the beneficial effects of curcumin as an adjunct to oxaliplatin, though dose, combination ratio and the timing of exposure to the agents are covariates that may affect the therapeutic efficacy and need to be determined. This review provides a summary of the studies investigating the effects of curcumin and its analogues, as adjuvants to oxaliplatin treatment in malignant cell lines and experimental tumor models. Addition of curcumin as an adjunct to oxaliplatin enhances oxaliplatin's toxicity in malignant cells, which potentially allows an oxaliplatin dose reduction and decreasing the adverse effects of chemotherapy. Curcumin has also been studied in several nonmalignant cell types and has been shown to exert cytoprotective properties against oxaliplatin's off-target toxicities. Despite all of the promising evidence to date, there is a scarcity of supportive evidence from clinical trials on the adjuvant use of curcumin, which needs future translational and clinical studies.

KW - Adjuvant

KW - Chemotherapy

KW - Curcumin

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=85059948213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059948213&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2019.01.020

DO - 10.1016/j.phrs.2019.01.020

M3 - Review article

AN - SCOPUS:85059948213

VL - 141

SP - 343

EP - 356

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

ER -